España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Galapagos
GLPGF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$23.01
-0.68
-2.86%
At close: -
Get Report
Comment
Galapagos (GLPGF) Forecast
News
Earnings
Galapagos (GLPGF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Galapagos (OTC:GLPGF) Stock
Galapagos Stock (OTC: GLPGF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, October 05, 2021
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
Vandana Singh
Monday, October 04, 2021
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
Vandana Singh
Tuesday, August 31, 2021
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
Vandana Singh
Thursday, July 15, 2021
Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study
Vandana Singh
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients
Vandana Singh
Friday, May 07, 2021
Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D Efforts
Vandana Singh
Thursday, March 04, 2021
Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies
Vandana Singh
Wednesday, February 10, 2021
Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials
Vandana Singh
Wednesday, February 19, 2020
Stocks That Hit 52-Week Highs On Wednesday
Lisa Levin
Tuesday, February 18, 2020
Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin
Thursday, February 06, 2020
Stocks That Hit 52-Week Highs On Thursday
Lisa Levin
Thursday, January 16, 2020
Stocks That Hit 52-Week Highs On Thursday
Lisa Levin
Friday, January 10, 2020
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Monday, July 29, 2019
New Equities that Broke Through 52-Week Highs Monday Morning
Lisa Levin
Monday, June 15, 2015
AbbVie, Galapagos Present Cystic Fibrosis Corrector and Potentiator Screening Approach at ECFS Conference
Benzinga
